385 related articles for article (PubMed ID: 27825460)
1. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
2. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
3. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
[TBL] [Abstract][Full Text] [Related]
4. Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.
Pals ST; Kersten MJ; Spaargaren M
Best Pract Res Clin Haematol; 2016 Jun; 29(2):161-168. PubMed ID: 27825462
[TBL] [Abstract][Full Text] [Related]
5. The bone marrow microenvironment in Waldenström macroglobulinemia.
Agarwal A; Ghobrial IM
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):218-21. PubMed ID: 23490994
[TBL] [Abstract][Full Text] [Related]
6. The bone marrow niche in Waldenström's macroglobulinemia.
Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa G; Roccaro A
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):118-20. PubMed ID: 21454209
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
8. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
9. [Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].
Sedlaříková L; Sadílková K; Kubiczková L; Hájek R; Sevčíková S
Klin Onkol; 2014; 27(1):18-23. PubMed ID: 24635433
[TBL] [Abstract][Full Text] [Related]
10. Cytokines in the microenvironment of Waldenström's macroglobulinemia.
Elsawa SF; Ansell SM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):43-5. PubMed ID: 19362970
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
Elsawa SF; Novak AJ; Ziesmer SC; Almada LL; Hodge LS; Grote DM; Witzig TE; Fernandez-Zapico ME; Ansell SM
Blood; 2011 Nov; 118(20):5540-9. PubMed ID: 21921047
[TBL] [Abstract][Full Text] [Related]
12. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
Kyle RA; Ansell SM; Kapoor P
Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an animal model for Waldenström's macroglobulinemia.
Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
[TBL] [Abstract][Full Text] [Related]
16. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
17. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
[TBL] [Abstract][Full Text] [Related]
18. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
19. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry.
Ocio EM; del Carpio D; Caballero Á; Alonso J; Paiva B; Pesoa R; Villaescusa T; López-Anglada L; Vidriales B; García-Sanz R
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):93-5. PubMed ID: 21454201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
